Not all GLP-1s are approved for obesity treatment, and this analysis includes all FDA-approved GLP-1s, including those approved for obesity (Saxenda, Weogvy, Zepbound) as well as those approved for type 2 diabetes (see Table 1)
Source: New England Journal of Medicine - STEP 1 Trial 20% lower risk of heart attack and stroke SELECT trial showed semaglutide reduces major cardiovascular events (death, heart attack, stroke) by 20% in people with obesity
What Some Of The Evidence Shows So Far Stopping GLP-1 therapy often leads to weight regain
Only available if prescribed after an online consultation with a healthcare provider
Understanding liver enzymes diabetes risk is becoming increasingly important because these commonly ordered blood tests may help identify people Read More Beyond the FIB-4: Why Diabetes Care Is Becoming a Hepatology-Endocrinology Partnership May 20, 2026 Articles, Diabetes, Gastroenterology, Obesity, Obesity, Type 2 Diabetes, Type 2 Diabetes 1,764 views Screening for fatty liver disease in patients with diabetes is no longer limited to identifying elevated liver enzymes or calculating a fibrosis score during an annual visit
The goal is maximum consistent therapeutic effect
